Compound Profile
BPC 157
Synthetic peptide (gastric-derived sequence)
BPC 157 is a synthetic 15 amino acid peptide studied mainly in animal models for tissue repair and inflammation.
Review needed — Review before use if any apply: Active Cancer Or Cancer History (Theoretical Angiogenesis/Tumor Growth Concern), Pregnancy/Breastfeeding, Unsupervised RUO Product Use Without Physician Oversight. Details
At a glance
From this profile's structured data- Evidence
- Grade D
- Safety
- No large-scale human safety trials exist and long-term human safety is unknown.
- Profile context
- Angiogenesis Promotion (VEGFR2 Upregulation), Nitric Oxide Pathway Modulation, FAK-Paxillin Growth Factor Signaling
Next stepsWhere to go next — guides & comparisons
Continue reading
- If you want to browse more compounds → All compounds
Unapproved compound: FDA safety and compounding review
BPC-157 is not FDA-approved as a finished drug product. FDA’s Pharmacy Compounding Advisory Committee discussed BPC-157 on July 23, 2026; an advisory-committee discussion or recommendation is not the same as FDA approval or a final 503A bulks-list rule.
- FDA continues to flag limited safety information and potential immunogenicity and peptide-impurity concerns for compounded BPC-157.
- Human clinical evidence remains very limited; this profile is not a self-treatment guide.
- A research-use label does not establish FDA-reviewed identity, quality, safety, or effectiveness for human use.
Regulatory status
2026 federal and state regulatory context
Not FDA approved as a finished drug product; RUO labeled product is not legally intended for human consumption. Banned year round under WADA's S0 category.
Regulatory changelog
- 2023 04/2026: FDA Category 2 restricted (503A bulk substances). 2026 04 22: Removed from Category 2 after nomination withdrawals; this did not place BPC 157 on the 503A Bulks List. 2026 07 23: FDA PCAC voted to recommend BPC 157 related bulk drug substances for the 503A Bulks List. The advisory recommendation is non binding and did not itself create a final 503A rule; as of 2026 08 26, no final FDA rule adding BPC 157 was located.
Quick stats
- Evidence level
- Preliminary evidence
- Typical onset
- Varies by prep
- Safety rating
- Review needed: Safety review pending
- Best for
- Angiogenesis Promotion (VEGFR2 Upregulation), Nitric Oxide Pathway Modulation, FAK Paxillin Growth Factor Signaling
- Avoid / review if
- Active Cancer Or Cancer History (Theoretical Angiogenesis/Tumor Growth Concern), Pregnancy/Breastfeeding, Unsupervised RUO Product Use Without Physician Oversight
Safety
Safety & Cautions
Review before use if any apply: Active Cancer Or Cancer History (Theoretical Angiogenesis/Tumor Growth Concern), Pregnancy/Breastfeeding, Unsupervised RUO Product Use Without Physician Oversight.
High caution
Caution level: High. Multiple caution categories apply, or the record uses avoid/contraindication language.
- Interaction-AwareMedication or interaction context is explicitly noted.
- Pregnancy/Breastfeeding CautionPregnancy or breastfeeding caution language is present.
Evidence Summary
Profile-wide ·D PreliminaryEvidence lens
Early signal that needs stronger human replication before practical claims.
Human clinical evidence: Not the primary signal
Mechanistic / preclinical: Mechanism mapped — Angiogenesis Promotion (VEGFR2 Upregulation) · Nitric Oxide Pathway Modulation · FAK Paxillin Growth Factor Signaling
Research maturity: Theoretical / mechanistic research — Mechanistic or unresolved evidence is kept separate from established human outcomes.
Safety boundary: Safety note available — Review before use if any apply: Active Cancer Or Cancer History (Theoretical Angiogenesis/Tumor Growth Concern), Pregnancy/Breastfeeding, Unsupervised RUO Product Use Without Physician Oversight.
Confidence estimate based on the design quality and consistency of published clinical trials.
BPC 157 has a preliminary evidence rating.
How evidence grades work
Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.
- Strong
- Multiple RCTs, consistent direction, adequate effect size
- Moderate
- Some RCTs or consistent observational data in humans
- Preliminary / Mixed
- Animal or in-vitro only, or conflicting human data
- Traditional / Theoretical
- Traditional use only; no controlled human trials
How BPC 157 Works
Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.
Mechanism Pathway — How BPC 157 Works
Dosing
- No standardized dose
- No established consumer dosing protocol; see full guide article for regulatory and safety context.
Mechanisms & biological pathways
Preclinical mechanism details from scientific profiles; these represent plausible pathways but do not guarantee clinical efficacy in humans.
- Angiogenesis Promotion (VEGFR2 Upregulation)
- Nitric Oxide Pathway Modulation
- FAK Paxillin Growth Factor Signaling
- Anti Inflammatory Cytokine Modulation
- Angiogenesis
- Tissue Repair Signaling
Compare & Sourcing
Compare side-by-side tradeoffs or verify active marker guidelines.
Free safety checklist
Get the BPC 157 evidence notes
Occasional research updates, safety context, and product-quality checks for supplement decisions.
We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.
Sourcing options disabled for safety
Direct product recommendations and affiliate links are suppressed for this compound due to its high caution or needs-review safety classification.
Evaluate the safety checks, contraindications, and potential medication interactions above under clinician supervision before use.
Safety first · Harm reduction
This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.
Learn how we evaluate confidence, safety, and intensity on the methodology page.
Editorial Review
Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.
Help improve this profile
Was this useful for your research?
These controls record only the page and the structured choice you make when analytics consent is enabled. Please don’t include personal medical information in research requests.
Was this evidence summary clear?
Did you find what you were researching?
Compound profile context
How to interpret BPC 157
BPC 157 compound profile with evidence context, key research topics, source notes, safety context, and references presented in an evidence-first format. Use this compound profile to understand mechanism, evidence quality, and practical safety context before comparing products or building a stack. A biochemical pathway connection can be useful for discovery, but it is not the same as proven benefit in humans.
When reviewing BPC 157, separate the active molecule from the product category around it. Dose form, absorption, extract standardization, medication interactions, and individual sensitivity can change the real-world risk-benefit picture.
For supplement planning, avoid combining multiple compounds with overlapping sedating, stimulating, serotonergic, blood-pressure, anticoagulant, or liver-metabolism effects unless a qualified clinician has reviewed the context.